Archives

Choose a date range

From To

Choose one or more categories

Categories:



 


Mount Sinai Medical Center appoints chair, board members

Monday, February 6, 2012 02:55 PM

Wayne E. Chaplin, president and COO of Southern Wine & Spirits of America, is the new chairman of the Mount Sinai Medical Center board of trustees. Chaplin previously served as the past vice chair of the executive committee at Mount Sinai.

More... »

Stephan Henauer to head i3 Pharma Resourcing in Europe

Monday, February 6, 2012 02:52 PM

PharmaNet/i3, inVentiv Health’s clinical segment, has appointed Stephan Henauer, M.D., executive director of i3 Pharma Resourcing. Henauer will lead the company’s staffing business in central, eastern and northern Europe.

More... »

HemoShear appoints Figler scientific director

Monday, February 6, 2012 02:50 PM

HemoShear, a biotechnology research company, has appointed Robert A. Figler, Ph.D., scientific director.

More... »

Study links coffee, genetics and Parkinson's disease prevention

Monday, February 6, 2012 02:30 PM

A recent study co-authored by Evergreen Healthcare neurologist Dr. Pinky Agarwal finds good news for coffee drinkers: consuming caffeinated coffee may significantly reduce the risk of Parkinson's disease in some individuals depending on their genetics, according to research recently published by the Public Library of Science.

More... »

Inherited risk factors for childhood leukemia more common in Hispanic patients

Monday, February 6, 2012 02:19 PM

Hispanic children are more likely than those from other racial and ethnic backgrounds to be diagnosed with acute lymphoblastic leukemia (ALL) and are more likely to die of their disease, found a study conducted by the Children’s Oncology Group and St Jude Children’s Hospital.

More... »

Henry Ford Hospital first in U.S. to start trial in aggressive brain tumors

Monday, February 6, 2012 02:12 PM

Henry Ford Hospital's Hermelin Brain Tumor Center is the first U.S. hospital to start a new clinical trial for Toca 511 & Toca FC, a combination therapy under investigation for high-grade glioma (HGG), a fast growing, brain cancer that often recurs even after surgery, radiation treatment and chemotherapy.

More... »

Bayer initiates expanded access program for radium-223 chloride

Monday, February 6, 2012 02:11 PM

The FDA has approved of Bayer Healthcare proceeding with its expanded access program to provide the investigational drug radium-223 chloride to patients diagnosed with castration-resistant prostate cancer (CRPC) and hormone-refractory prostate cancer (HRPC) with symptomatic bone metastases.

More... »

Alize licenses Asparec therapy for treatment of leukemia

Monday, February 6, 2012 02:08 PM

Alize Pharma II, a drug development company focused on oncology and metabolism and part of the Alize Pharma group, has signed a license agreement with EUSA Pharma for Asparec, a new L-asparaginase product currently in phase I clinical development for the treatment of acute lymphoblastic leukemia.
 
Pursuant to the agreement, EUSA will be responsible for the development and worldwide commercialization of Asparec, targeted at patients with Acute Lymphoblastic Leukemia who are hypersensitive to E. coli-derived L-asparaginase. In return, Alize has received an upfront payment and will be entitled to additional regulatory milestone payments and royalties on sales. The companies have not disclosed further financial information.

“This agreement between Alize Pharma and EUSA Pharma,” said Alize Pharma’s president and founder, Thierry Abribat, “validates our medical approach, emphasizes our drug development capabilities and fits well with our business strategy, which is to establish partnerships with the pharmaceutical industry early in the development of our programs in order to secure both near-term and long-term revenue streams.”

More... »

New bipartisan legislation to address prescription drug shortages

Monday, February 6, 2012 01:58 PM

U.S. Representatives John Carney (D-Del.) and Larry Bucshon (R-Ind.) introduced the Drug Shortage Prevention Act Jan. 31, which addresses the scarcity of certain pharmaceutical drugs in the marketplace.

More... »

Pfizer recalls birth control due to out of order tablets

Monday, February 6, 2012 01:56 PM

Pfizer has voluntarily recalled 14 lots of Lo/Ovral-28 (norgestrel and ethinyl estradiol) tablets and 14 lots of Norgestrel and Ethinyl Estradiol tablets (generic) on the U.S. market—approximately 1 million packs.

More... »

CWWeekly

February 6

Prism Ideas, dMetrics team up to launch service to evaluate patient outcomes reported in social media

Researchers: Unreported trial data problematic for safety and efficacy of approved drugs

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

February

Anticipating the rise of virtual drug development
With the rising cost of drug development and a continued shortage of new products entering the marketplace, the virtual pharma model is expected to become more prevalent going forward, particularly as pharma companies have...

Closing investigative site operations a complex process
In light of the shrinking investigative site landscape, CenterWatch has conducted in-depth case studies of sites closing their operations. Site personnel offer insights into...

Eye On Shire
Shire is a rapidly growing, global specialty biopharmaceutical company, directly marketing its products in over 50 countries...

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

Copyright © 1995-2012 CenterWatch.